Long-Term Treatment with Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B

Eugene R. Schiff,Samuel S. Lee,You-Chen Chao,Seung Kew Yoon,Fernando Bessone,Shun-Sheng Wu,Wieslaw Kryczka,Yoav Lurie,Adrian Gadano,George Kitis,Suzanne Beebe,Dong Xu,Hong Tang,Uchenna Iloeje

DOI: https://doi.org/10.1016/j.cgh.2010.11.040

IF: 13.576

2011-01-01

Clinical Gastroenterology and Hepatology

Abstract:BACKGROUND & AIMS: Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. Patients with advanced fibrosis or cirrhosis, who received long-term entecavir treatment, were evaluated for improvement in liver histology. METHODS: The study included a subset of patients from phase III and long-term rollover studies, who received entecavir for at least 3 years, had advanced fibrosis or cirrhosis, and evaluable biopsies at baseline and after long-term treatment. RESULTS: Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score, 4). After approximately 6 years of cumulative entecavir therapy (range, 267‐297 wk), all 10 patients showed improvement in liver histology and Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and Knodell necroinflammatory scores were 2.2 and 7.6, respectively. A reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients who had cirrhosis at baseline. CONCLUSIONS: Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated histologic improvement and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.